Adagrasib

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Adagrasib is an onp drug catalogued in DrugCentral. It was first approved by the FDA in 2022. DrugCentral lists 1 molecular target, including KRAS. Recorded indications include KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

• Approval status: onp (first approved 2022 by the FDA).
• Molecular targets: KRAS (1 listed in DrugCentral).
• Indications: KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
• ATC code: L01XX77 (Other antineoplastic agents).
• Molecular formula: C32H35ClFN7O2; molecular weight 604.13 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer

Mechanism & targets

Molecular targets (1)

Target	Gene	Action	Activity
GTPase KRas	KRAS	inhibitor	IC50 7.85

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2022-12-12	FDA	—	MIRATI THERAPEUTICS, INC	Yes

ATC classification

ATC code	Therapeutic hierarchy
L01XX77	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Other antineoplastic agents

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: KRAS · Testing Required
• FDA label: KRAS · Testing Required
• HCSC label

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Death	309.2
Hospitalisation	72.0

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Adagrasib is on its molecule page.

• Molecular formula: C₃₂H₃₅ClFN₇O₂
• Molecular weight: 604.13 g/mol
• CAS number: —
• InChIKey: PEMUGDMSUDYLHU-ZEQRLZLVSA-N
• PubChem CID: 138611145

CN1CCC[C@H]1COC1=NC2=C(CCN(C2)C2=CC=CC3=CC=CC(Cl)=C23)C(=N1)N1CCN([C@@H](CC#N)C1)C(=O)C(F)=C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Adagrasib used for?

DrugCentral lists the following indications for Adagrasib: KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

How does Adagrasib work?

Its molecular targets in DrugCentral include KRAS (inhibitor).

When was Adagrasib first approved?

Adagrasib was first approved by the FDA in 2022.

What is the chemical formula of Adagrasib?

Adagrasib has the molecular formula C32H35ClFN7O2 and a molecular weight of 604.13 g/mol.

Sources

• DrugCentral drug card 5694 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL4594350 — compound record and bioactivity
• PubChem CID 138611145 — chemical identifiers
• DrugBank DB15568 — drug record
• FDA UNII 8EOO6HQF8Y — substance identity
• DailyMed: FDA labels for Adagrasib — current prescribing information (label search)
• UniProt P01116 (KRAS) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.